Extended Data Figure 2: Suz12 and Nf1 mutations cooperate to promote widespread tumour development in mice.
From: PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies

a, Semi-quantitative PCR showing loss of the WT Suz12 and Nf1 allele in Nf1/Suz12 mouse tumours. b, Table listing the tumours observed in Nf1+/−; Suz12+/− and Suz12+/− mice. Tumour types denoted with a red asterisk occur in patients with NF1 and an increased frequency in patients with NF1 microdeletions. Tumour types denoted with a blue asterisk represent spontaneous tumour types/lesions that have been shown to harbour NF1 mutations humans. c, Semi-quantitative PCR showing loss of the WT Suz12, Nf1 and p53 allele in Nf1/p53/Suz12 mouse MPNST. d, Haematoxylin and eosin staining of a GBM from an Nf1/p53/Suz12 mouse.